Navigation Links
Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/2/2009

ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that Richard Garr, CEO and President, will present at the 11th Annual BIO CEO & Investor Conference to be held on February 9-10, 2009, at the Waldorf=Astoria Hotel, New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO)

Neuralstem's presentation is scheduled for Monday, February 9, 2009 at 10:00 a.m. Eastern Time.

The presentation will be webcast live and will be available on the Investor Relations section of Neuralstem's website at www.neuralstem.com. For those who are not available to listen to the live broadcast, the call will be archived.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis i
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Reports Second Quarter Financial Results and Highlights
4. Neuralstem Fills Key Product Development Position
5. Neuralstem Responds to New StemCells, Inc. Lawsuit
6. Neuralstem Sues StemCells, Inc. Over New Patent
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
9. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
10. Neuralstem Shares Accepted for Trading on Amex(R)
11. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... March 31 DOR BioPharma, Inc. (OTC Bulletin Board: ... today announced its financial results for 2008. DOR,s revenues ... million in 2007. The increase was due primarily ... the resulting achievement of certain research and development milestones ...
... IDM Pharma, Inc. (Nasdaq: IDMI ) today ... ended December 31, 2008. Financial information presented represents the ... Pharma S.A.Total revenues in the quarter ended December 31, 2008 ... $0.07 per share for the quarter. Total revenues for ...
... leader of cell line manufacturing, Selexis is now ... recombinant protein drugs with added characterization servicesGENEVA, March ... offering technologies and services for the rapid development ... an expanded offering focusing on the biosimilar market ...
Cached Biology Technology:DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5IDM Pharma Reports 2008 Financial Results 2IDM Pharma Reports 2008 Financial Results 3IDM Pharma Reports 2008 Financial Results 4IDM Pharma Reports 2008 Financial Results 5IDM Pharma Reports 2008 Financial Results 6IDM Pharma Reports 2008 Financial Results 7IDM Pharma Reports 2008 Financial Results 8Selexis Launches Biosimilar Cell Line Development Program 2
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Want to slow the signs of aging and live ... calories could be a promising strategy. Calorie restriction ... rats and mice. While scientists do not know how calorie ... is that it slows aging by decreasing a thyroid hormone, ...
... a bold commitment from Germany, leaders of the world,s ... Summit in Japan to take immediate and substantive action ... pledge of 500 million Euros over four years to ... forest protection, starts to address a major source of ...
... COLLEGE STATION, July 2, 2008 -- Two Texas A&M ... help scientists more accurately study complex units of clustered ... scientists to analyze many bacterial genomes at once, is ... experimentally validated data instead of from statistical predictions, they ...
Cached Biology News:Looking for the Founatain of Youth? Cut your calories, research suggests 2G8 summit: Opportunity for immediate action on climate change 2G8 summit: Opportunity for immediate action on climate change 3Texas A&M researchers develop tool to study complex clusters of genes 2Texas A&M researchers develop tool to study complex clusters of genes 3
... have moderate chemiluminescence efficiencies and the chemistry ... have the added benefit that they require ... the background signal. This benefit has been ... immunoassay applications. These compounds can also be ...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... version of Freezerworks Unlimited includes 2 clients and ... facilitates the sharing of freezers by multiple groups ... Network Client/Server version ... in monitor with 256 colors; OS 8.6 & ...
Biology Products: